116 related articles for article (PubMed ID: 2554522)
1. Antithrombin III and hepatocellular carcinoma.
Lefrère JJ; Conard J; Lerable J; Samama M
Thromb Haemost; 1989 Sep; 62(2):817. PubMed ID: 2554522
[No Abstract] [Full Text] [Related]
2. [Focus on a new assay of fucosylated alpha-fetoprotein and evaluation in the biological diagnosis of hepatocellular carcinoma in cirrhosis].
Denis I; Beaudonnet A; Pichot J; Roubille M; Gelineau M
Ann Biol Clin (Paris); 2000; 58(1):85-90. PubMed ID: 10673618
[No Abstract] [Full Text] [Related]
3. Antithrombin III in patients with hepatocellular carcinoma.
Leone G; De Stefano V; Garufi C; Ferrelli R; Cassano A; Grieco A
Thromb Haemost; 1987 Dec; 58(4):1093. PubMed ID: 2832966
[No Abstract] [Full Text] [Related]
4. Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis.
Chan KK; Chlebowski RT; Tong M; Chen HS; Gross JF; Bateman JR
Cancer Res; 1980 Apr; 40(4):1263-8. PubMed ID: 6244090
[No Abstract] [Full Text] [Related]
5. [N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus].
Liu XE; Desmyter L; Gao CF; Laroy W; Dewaele S; Vanhooren V; Wang L; Zhuang H; Callewaert N; Libert C; Contreras R; Chen CY
Zhonghua Gan Zang Bing Za Zhi; 2008 Jan; 16(1):74-5. PubMed ID: 18226355
[No Abstract] [Full Text] [Related]
6. May plasma cholesterol level be considered a neoplastic marker in liver disease from cirrhosis to hepatocellular carcinoma?
Venturini I; Amedei R; Modonesi G; Cosenza R; Miglioli L; Cioni G; Zeneroli ML
Ital J Gastroenterol Hepatol; 1999; 31(1):61-5. PubMed ID: 10091105
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of serum copper, zinc and plasma fibrinogen in cirrhotic patients with and without hepatocellular carcinoma.
Doğan UB; Cindoruk M; Dumlu S; Unlü R; Unal S
Ital J Gastroenterol Hepatol; 1997 Oct; 29(5):476-7. PubMed ID: 9494860
[No Abstract] [Full Text] [Related]
8. Serum selenium concentration in patients with liver cirrhosis and hepatocellular carcinoma.
Buljevac M; Romić Z; Vucelić B; Banić M; Krznarić Z; Plesko S
Acta Med Croatica; 1996; 50(1):11-4. PubMed ID: 8776109
[TBL] [Abstract][Full Text] [Related]
9. Early detection of hepatoma in cirrhosis by serial quantitation of alpha-1-foetoprotein in serum.
Niermeijer P; Gips CH; Marrink J; QUE GS
Neth J Med; 1976; 19(1):25-8. PubMed ID: 55985
[No Abstract] [Full Text] [Related]
10. Early detection of hepatoma in cirrhosis by serial quantitation of alpha-1-foetoprotein in serum.
Niermeijer P; Gips CH; Marrink J; Qué GS
Neth J Med; 1976; 19(1):15-8. PubMed ID: 55984
[No Abstract] [Full Text] [Related]
11. Primary liver cell carcinoma and post-necrotic cirrhosis associated with Australia antigen and alpha-feto protein. (A case report).
Malaviya AN; Nayak NC
J Assoc Physicians India; 1971 Oct; 19(10):697-700. PubMed ID: 4332064
[No Abstract] [Full Text] [Related]
12. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases.
Paradis V; Degos F; Dargère D; Pham N; Belghiti J; Degott C; Janeau JL; Bezeaud A; Delforge D; Cubizolles M; Laurendeau I; Bedossa P
Hepatology; 2005 Jan; 41(1):40-7. PubMed ID: 15690480
[TBL] [Abstract][Full Text] [Related]
13. Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis.
Henry L; Lavabre-Bertrand T; Vercambre L; Ramos J; Carillo S; Guiraud I; Pouderoux P; Bismuth M; Valats JC; Demattei C; Duny Y; Chaze I; Funakoshi N; Bureau JP; Daurès JP; Blanc P
Gut; 2009 Jun; 58(6):833-8. PubMed ID: 19201777
[TBL] [Abstract][Full Text] [Related]
14. Increased IGF-I : IGFBP-3 ratio in patients with hepatocellular carcinoma.
Mattera D; Capuano G; Colao A; Pivonello R; Manguso F; Puzziello A; D'Agostino L
Clin Endocrinol (Oxf); 2003 Dec; 59(6):699-706. PubMed ID: 14974910
[TBL] [Abstract][Full Text] [Related]
15. [Screening for hepatocellular carcinoma].
Leone N; Rizzetto M
Minerva Med; 2005 Apr; 96(2):95-108. PubMed ID: 16172579
[TBL] [Abstract][Full Text] [Related]
16. Plasma amino acid levels in patients with colorectal cancers and liver cirrhosis with hepatocellular carcinoma.
Lee JC; Chen MJ; Chang CH; Tiai YF; Lin PW; Lai HS; Wang ST
Hepatogastroenterology; 2003; 50(53):1269-73. PubMed ID: 14571716
[TBL] [Abstract][Full Text] [Related]
17. Decreased disappearance rate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) from the blood and its unresponsiveness to tocophreyl nicotinate and indomethacin in patients with primary hepatocellular carcinoma.
Hobara N; Watanabe A
Acta Med Okayama; 1979 Oct; 33(5):389-93. PubMed ID: 229696
[TBL] [Abstract][Full Text] [Related]
18. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of circulating intercellular adhesion molecule 1 in hepatocellular carcinoma.
Hamazaki K; Gochi A; Shimamura H; Kaihara A; Maruo Y; Doi Y; Orita K; Lygidakis NJ
Hepatogastroenterology; 1996; 43(7):229-34. PubMed ID: 8682469
[TBL] [Abstract][Full Text] [Related]
20. [Hepatocellular carcinoma with cirrhosis: treatment with doxorubicin. Phase II evaluation].
Barbare JC; Ballet F; Petit J; Poupon R; Darnis F
Bull Cancer; 1984; 71(5):442-5. PubMed ID: 6084528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
